Clinical Trials in Mersin, Turkey (Türkiye)
78 recruiting
Showing 1–20 of 93 trials
Recruiting
Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled174 locationsNCT07060807
Recruiting
Phase 3
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Essential Thrombocythemia
Merck Sharp & Dohme LLC340 enrolled163 locationsNCT06079879
Recruiting
Phase 3
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
Sickle Cell Disease
Sanofi192 enrolled54 locationsNCT06975865
Recruiting
TRIMPACT: Real-World First-Line Atezolizumab Use in Stage IV NSCLC With PD-L1 ≥50%
NSCLC Stage IVPD-L1 Gene MutationAtezolizumab+1 more
Antalya Training and Research Hospital150 enrolled25 locationsNCT07279402
Recruiting
Phase 3
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
Heart Failure
Boehringer Ingelheim6,000 enrolled653 locationsNCT06424288
Recruiting
Phase 3
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
Heart Failure
Boehringer Ingelheim4,200 enrolled638 locationsNCT06935370
Recruiting
Phase 3
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Primary Biliary Cholangitis
Gilead Sciences318 enrolled196 locationsNCT06051617
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Ulcerative Colitis
Colitis Ulcerative
Sanofi204 enrolled115 locationsNCT06867094
Recruiting
Phase 3
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
Ph+ ALLLeukemia, Lymphoblastic, Acute, Philadelphia-Positive
Ascentage Pharma Group Inc.350 enrolled90 locationsNCT06051409
Recruiting
Phase 3
Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals50 enrolled31 locationsNCT05935215
Recruiting
Phase 3
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
IC-MPGN
Novartis Pharmaceuticals106 enrolled127 locationsNCT05755386
Recruiting
Phase 3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Non-small Cell Lung CancerNSCLC
Merck Sharp & Dohme LLC851 enrolled207 locationsNCT06422143
Recruiting
Phase 3
A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
Sickle Cell Disease
Novo Nordisk A/S408 enrolled172 locationsNCT06612268
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled536 locationsNCT06492616
Recruiting
Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled166 locationsNCT07190209
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Crohn's Disease
Sanofi260 enrolled138 locationsNCT06637631
Recruiting
Providing Grandchild Care in Later Life
Child Care
Mersin University138 enrolled1 locationNCT07501260
Recruiting
Phase 2
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
Ulcerative ColitisUlcerative Colitis Chronic
Eli Lilly and Company140 enrolled207 locationsNCT06598943
Recruiting
Phase 2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active Severe
Eli Lilly and Company1,431 enrolled251 locationsNCT07415044
Recruiting
Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled191 locationsNCT06937086